Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin.

Sechaud, R and Robeva, A and Belleli, R and Balez, S (2008) Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin. International journal of clinical pharmacology and therapeutics, 46 (10). pp. 519-526. ISSN 0946-1965

Abstract

Deferasirox (Exjade, ICL670) is a potent iron chelator, recently approved as first-line therapy for the treatment of blood-transfusion-related iron overload. Iron deposition in the heart may lead to cardiac dysfunction in patients with iron overload. Thus, the combination of cardiac glycosides and deferasirox is likely to be used in clinical practice.

Item Type: Article
Date Deposited: 28 Jan 2012 00:45
Last Modified: 28 Jan 2012 00:45
URI: https://oak.novartis.com/id/eprint/5503

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.